Dr. Jerry A. Molitor, MD
Rheumatology (Rheumatology Physician)
516 Delaware Street Se, Clinic 6a, Ump Medicine Specialties Clinic
Minneapolis, MN 55455
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 55
Licensed in Washington since 1997, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
WA license MD00035031 (first issued 1997; expired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- M Health Fairview University of Mn Medical Center Minneapolis, MN
- M Health Fairview Southdale Hospital Edina, MN
- M Health Fairview Ridges Hospital Burnsville, MN
Medical groups
- Fairview Express Care (1,911 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 55
- Services billed
- 191
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 66 | 47 |
| Established patient office or other outpatient visit, 40-54 minutes | 27 | 21 |
| Insertion of needle into vein for collection of blood sample | 20 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $2,724 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,724 |
|---|
| Consulting Fee | $2,480 |
|---|---|
| Travel and Lodging | $140 |
| Food and Beverage | $104 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 2, 2025 | Consulting Fee | $2,480 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $140 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $74,360 in research payments for these studies, mostly to the institutions running them.
- A Multicenter,Randomized,Double blind,Placebo controlled,Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Systemic Sclerosis
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.